https://www.cdc.gov/immigrantrefugeehealth/guidelines/overseas-guidelines.html

Summary of Recommendations

This guidance is intended for the International Organization for Migration (IOM) physicians and other panel physicians who administer overseas predeparture presumptive treatment for intestinal parasites, but may also be referenced by U.S. medical providers caring for refugees who will be receiving presumptive treatment after they arrive in the United States.

While these recommendations have been implemented in many overseas sites, logistical and procurement issues still limit their full implementation in some. All Middle Eastern, Asian, North African, Latin American, and Caribbean refugees should receive presumptive therapy with:

All Middle Eastern, Asian, North African, Latin American, and Caribbean refugees should receive presumptive therapy with:
    Albendazole, single dose of 400 mg (200 mg for children 12-23 months)
    AND
    Ivermectin, two doses 200 mcg/Kg orally once a day for 2 days before departure to the United States.
All African refugees who did not originate from or reside in countries where Loa loa infection is endemic (Box 1) should receive presumptive therapy with:
    Albendazole, single dose of 400 mg (200 mg for children 12-23 months)
    AND
    Ivermectin, two doses 200 mcg/Kg orally once a day for 2 days
    AND
    Praziquantel, 40 mg/kg, which may be divided in two doses before refugees depart for the United States.
All sub-Saharan African refugees who originated from or resided in countries where Loa loa infection is endemic (Box 1) should receive presumptive therapy with:
    Albendazole, single dose of 400 mg (200 mg for children 12-23 months)
    AND
    Praziquantel, 40 mg/kg, which may be divided in two doses before departure to the United States.
    Refugees from Loa loa-endemic countries (Box 1) in Africa should not receive presumptive ivermectin for strongyloidiasis prior to departure. Management of Strongyloides should be deferred until arrival in the United States, unless Loa loa is excluded by reviewing a daytime (10 AM to 2 PM) Giemsa-stained blood smear. Deferral of treatment for Strongyloides until after the refugee arrives in the United States is acceptable. Guidance is available for management of Strongyloides following arrival in the United States in the Domestic Intestinal Parasite Screening Guidance.
Special instructions:
    Pre-departure presumptive and directed malaria treatment regimens must be administered as directly observed therapy.
    Test results and pre-departure treatment should be documented on the pre-departure medical screening form. If treatment was not administered, this should be clearly indicated along with the reason that treatment was not administered.

https://www.cdc.gov/immigrantrefugeehealth/pdf/intestinal-parasites-overseas.pdf

3 Summary of Recommendations These guidelines are recommendations for the International Organization for Migration (IOM) physicians and other panel physicians who administer overseas predeparture presumptive treatment for intestinal parasites. While most recommendations have been implemented, not all refugee populations listed in this document are receiving all recommended pre-departure medications, due to funding restrictions and logistical challenges. For current implementation status in specific populations, see the Treatment Schedules for Presumptive Parasitic Infections for U.S.-Bound Refugees, administered by IOM. The recommendations in these guidelines may also be referenced by U.S. medical providers caring for refugees who will be receiving presumptive treatment after they arrive in the United States. • All Middle Eastern, Asian, North African, Latin American, and Caribbean refugees, with exceptions noted in this document, should receive presumptive therapy with: o Albendazole, single dose of 400 mg (200 mg for children 12-23 months) AND o Ivermectin, two doses 200 mcg/Kg orally once a day for 2 days before departure to the United States. • All African refugees who did not originate from or reside in countries where Loa loa infection is endemic (Box 1), with exceptions noted in this document, should receive presumptive therapy with: o Albendazole, single dose of 400 mg (200 mg for children 12-23 months) AND o Ivermectin, two doses 200 mcg/Kg orally once a day for 2 days AND o Praziquantel, 40 mg/kg, which may be divided in two doses before refugees depart for the United States. • All sub-Saharan African refugees who originated from or resided in countries where Loa loa infection is endemic (Box 1), with exceptions noted in this document, should receive presumptive therapy with: o Albendazole, single dose of 400 mg (200 mg for children 12-23 months) AND o Praziquantel, 40 mg/kg, which may be divided in two doses before departure to the United States. o Refugees from Loa loa-endemic countries (Box 1) in Africa should not receive presumptive ivermectin for strongyloidiasis prior to departure. Management of Strongyloides should be deferred until arrival in the United States, unless Loa loa is excluded by reviewing a daytime (10 AM to 2 PM) Giemsa-stained blood smear. Deferral of treatment for Strongyloides until after the refugee arrives in the United States is acceptable. Guidance is available for management of Strongyloides following arrival in the Unite